Skip to main content

Stiripentol in the Management of Epilepsy

CNS Drugs volume 31, pages 405–416 (2017)Cite this article

Abstract

Stiripentol is a structurally unique antiepileptic drug that has several possible mechanisms of action, including diverse effects on the gamma-aminobutyric acid (GABA)-A receptor and novel inhibition of lactate dehydrogenase. Because of its inhibition of several cytochrome P450 enzymes, it has extensive pharmacokinetic interactions, which often necessitates reduction in doses of certain co-therapies, particularly clobazam. Stiripentol also has a neuroprotective action, by reducing calcium-mediated neurotoxicity. Evidence of its efficacy is most robust for Dravet syndrome, where stiripentol added to clobazam and valproic acid reduces seizure frequency and severity in the majority of cases. Small case series have also suggested benefit for malignant migrating partial seizures in infancy, super-refractory status epilepticus, and intractable focal epilepsy, although larger prospective studies are needed in these disorders.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. May TW, Boor R, Mayer T, Jurgens U, Rambeck B, Holert N, et al. Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2012;34:390–7.

    CAS  Article  PubMed  Google Scholar 

  2. Farwell JR, Anderson GD, Kerr BM, Tor JA, Levy RH. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia. 1993;34:305–11.

    CAS  Article  PubMed  Google Scholar 

  3. Jacob S, Nair AB. An updated overview on therapeutic drug monitoring of recent antiepileptic drugs. Drugs R D. 2016;16:303–16.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Darwish HW, Abdelhameed AS, Attia MI, Bakheit AH, Khalil NY, Al-Majed AA. A stability-indicating HPLC-DAD method for determination of stiripentol: development, validation, kinetics, structure elucidation and application to commercial dosage form. J Anal Methods Chem. 2014;2014:638951.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Chiron C. Stiripentol. Expert Opin Investig Drugs. 2005;14:905–11.

    CAS  Article  PubMed  Google Scholar 

  6. Moreland TA, Astoin J, Lepage F, Tombret F, Levy RH, Baillie TA. The metabolic fate of stiripentol in man. Drug Metab Dispos. 1986;14:654–62.

    CAS  PubMed  Google Scholar 

  7. Levy RH, Lin HS, Blehaut HM, Tor JA. Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity. J Clin Pharmacol. 1983;23:523–33.

    CAS  Article  PubMed  Google Scholar 

  8. Levy RH, Loiseau P, Guyot M, Blehaut HM, Tor J, Moreland TA. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther. 1984;36:661–9.

    CAS  Article  PubMed  Google Scholar 

  9. Peigne S, Rey E, Le Guern ME, Dulac O, Chiron C, Pons G, et al. Reassessment of stiripentol pharmacokinetics in healthy adult volunteers. Epilepsy Res. 2014;108:909–16.

    CAS  Article  PubMed  Google Scholar 

  10. Quilichini PP, Chiron C, Ben-Ari Y, Gozlan H. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006;47:704–16.

    CAS  Article  PubMed  Google Scholar 

  11. Fisher JL. The anti-convulsant stiripentol acts directly on the GABA (A) receptor as a positive allosteric modulator. Neuropharmacology. 2009;56:190–7.

    CAS  Article  PubMed  Google Scholar 

  12. Laurie DJ, Wisden W, Seeburg PH. The distribution of thirteen GABAA receptor subunit mRNAs in the rat brain. III. Embryonic and postnatal development. J Neurosci. 1992;12:4151–72.

    CAS  PubMed  Google Scholar 

  13. Fisher JL. The effects of stiripentol on GABA (A) receptors. Epilepsia. 2011;52(Suppl 2):76–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. Grosenbaugh DK, Mott DD. Stiripentol in refractory status epilepticus. Epilepsia. 2013;54(Suppl 6):103–5.

    CAS  Article  PubMed  Google Scholar 

  15. Goodkin HP, Joshi S, Mtchedlishvili Z, Brar J, Kapur J. Subunit-specific trafficking of GABA(A) receptors during status epilepticus. J Neurosci. 2008;28:2527–38.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. Rho JM. Inhibition of lactate dehydrogenase to treat epilepsy. N Engl J Med. 2015;373:187–9.

    Article  PubMed  Google Scholar 

  17. Sada N, Lee S, Katsu T, Otsuki T, Inoue T. Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science. 2015;347:1362–7.

    CAS  Article  PubMed  Google Scholar 

  18. Tran A, Vauzelle-Kervroedan F, Rey E, Pous G, d’Athis P, Chiron C, et al. Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children. Eur J Clin Pharmacol. 1996;50:497–500.

    CAS  Article  PubMed  Google Scholar 

  19. Cazali N, Tran A, Treluyer JM, Rey E, d’Athis P, Vincent J, et al. Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol. 2003;56:526–36.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. Mudigoudar B, Weatherspoon S, Wheless JW. Emerging antiepileptic drugs for severe pediatric epilepsies. Semin Pediatr Neurol. 2016;23:167–79.

    Article  PubMed  Google Scholar 

  21. Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther. 1998;284:356–61.

    CAS  PubMed  Google Scholar 

  22. Inoue Y, Ohtsuka Y, Oguni H, Tohyama J, Baba H, Fukushima K, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia. 2009;50:2362–8.

    CAS  Article  PubMed  Google Scholar 

  23. Kosaki K, Tamura K, Sato R, Samejima H, Tanigawara Y, Takahashi T. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev. 2004;26:530–4.

    Article  PubMed  Google Scholar 

  24. Kouga T, Shimbo H, Iai M, Yamashita S, Ishii A, Ihara Y, et al. Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome. Brain Dev. 2015;37:243–9.

    Article  PubMed  Google Scholar 

  25. Auvin S, Lecointe C, Dupuis N, Desnous B, Lebon S, Gressens P, et al. Stiripentol exhibits higher anticonvulsant properties in the immature than in the mature rat brain. Epilepsia. 2013;54:2082–90.

    CAS  Article  PubMed  Google Scholar 

  26. Verleye M, Buttigieg D, Steinschneider R. Neuroprotective activity of stiripentol with a possible involvement of voltage-dependent calcium and sodium channels. J Neurosci Res. 2016;94:179–89.

    CAS  Article  PubMed  Google Scholar 

  27. Perez J, Chiron C, Musial C, Rey E, Blehaut H, d’Athis P, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40:1618–26.

    CAS  Article  PubMed  Google Scholar 

  28. Chiron C, Tonnelier S, Rey E, Brunet ML, Tran A, d’Athis P, et al. Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design. J Child Neurol. 2006;21:496–502.

    Article  PubMed  Google Scholar 

  29. Inoue Y, Ohtsuka Y, Group S-S. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res. 2015;113:90–7.

    CAS  Article  PubMed  Google Scholar 

  30. Chiron C. Stiripentol. Neurotherapeutics. 2007;4:123–5.

    CAS  Article  PubMed  Google Scholar 

  31. Trojnar MK, Wojtal K, Trojnar MP, Czuczwar SJ. Stiripentol. A novel antiepileptic drug. Pharmacol Rep. 2005;57:154–60.

    CAS  PubMed  Google Scholar 

  32. Rascol O, Squalli A, Montastruc JL, Garat A, Houin G, Lachau S, et al. A pilot study of stiripentol, a new anticonvulsant drug, in complex partial seizures uncontrolled by carbamazepine. Clin Neuropharmacol. 1989;12:119–23.

    CAS  Article  PubMed  Google Scholar 

  33. Chiron C, Marchand MC, Tran A, Rey E, d’Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356:1638–42.

    CAS  Article  PubMed  Google Scholar 

  34. De Liso P, Chemaly N, Laschet J, Barnerias C, Hully M, Leunen D, et al. Patients with dravet syndrome in the era of stiripentol: a French cohort cross-sectional study. Epilepsy Res. 2016;125:42–6.

    Article  PubMed  Google Scholar 

  35. Aras LM, Isla J, Mingorance-Le Meur A. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome. Epilepsy Behav. 2015;44:104–9.

    Article  PubMed  Google Scholar 

  36. Thanh TN, Chiron C, Dellatolas G, Rey E, Pons G, Vincent J. et al [Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet’s syndrome)]. Arch Pediatr. 2002;9:1120–7.

    Article  PubMed  Google Scholar 

  37. Inoue Y, Ohtsuka Y. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence. Epilepsy Res. 2014;108:725–31.

    CAS  Article  PubMed  Google Scholar 

  38. Wirrell EC, Laux L, Franz DN, Sullivan J, Saneto RP, Morse RP, et al. Stiripentol in Dravet syndrome: results of a retrospective US study. Epilepsia. 2013;54:1595–604.

    CAS  Article  PubMed  Google Scholar 

  39. Balestrini S, Sisodiya SM. Audit of use of stiripentol in adults with Dravet syndrome. Acta Neurol Scand. 2017;135:73–9.

    CAS  Article  PubMed  Google Scholar 

  40. Coppola G. Malignant migrating partial seizures in infancy: an epilepsy syndrome of unknown etiology. Epilepsia. 2009;50(Suppl 5):49–51.

    Article  PubMed  Google Scholar 

  41. Ishii A, Shioda M, Okumura A, Kidokoro H, Sakauchi M, Shimada S, et al. A recurrent KCNT1 mutation in two sporadic cases with malignant migrating partial seizures in infancy. Gene. 2013;531:467–71.

    CAS  Article  PubMed  Google Scholar 

  42. Ohba C, Kato M, Takahashi S, Lerman-Sagie T, Lev D, Terashima H, et al. Early onset epileptic encephalopathy caused by de novo SCN8A mutations. Epilepsia. 2014;55:994–1000.

    CAS  Article  PubMed  Google Scholar 

  43. Poduri A, Chopra SS, Neilan EG, Elhosary PC, Kurian MA, Meyer E, et al. Homozygous PLCB1 deletion associated with malignant migrating partial seizures in infancy. Epilepsia. 2012;53:e146–50.

    CAS  Article  PubMed  Google Scholar 

  44. Carranza Rojo D, Hamiwka L, McMahon JM, Dibbens LM, Arsov T, Suls A, et al. De novo SCN1A mutations in migrating partial seizures of infancy. Neurology. 2011;77:380–3.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  45. Dhamija R, Wirrell E, Falcao G, Kirmani S, Wong-Kisiel LC. Novel de novo SCN2A mutation in a child with migrating focal seizures of infancy. Pediatr Neurol. 2013;49:486–8.

    Article  PubMed  Google Scholar 

  46. Milh M, Falace A, Villeneuve N, Vanni N, Cacciagli P, Assereto S, et al. Novel compound heterozygous mutations in TBC1D24 cause familial malignant migrating partial seizures of infancy. Hum Mutat. 2013;34:869–72.

    CAS  Article  PubMed  Google Scholar 

  47. Djuric M, Kravljanac R, Kovacevic G, Martic J. The efficacy of bromides, stiripentol and levetiracetam in two patients with malignant migrating partial seizures in infancy. Epileptic Disord. 2011;13:22–6.

    PubMed  Google Scholar 

  48. Merdariu D, Delanoe C, Mahfoufi N, Bellavoine V, Auvin S. Malignant migrating partial seizures of infancy controlled by stiripentol and clonazepam. Brain Dev. 2013;35:177–80.

    Article  PubMed  Google Scholar 

  49. Howell KB, McMahon JM, Carvill GL, Tambunan D, Mackay MT, Rodriguez-Casero V, et al. SCN2A encephalopathy: a major cause of epilepsy of infancy with migrating focal seizures. Neurology. 2015;85:958–66.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  50. Boerma RS, Braun KP, van den Broek MP, van Berkestijn FM, Swinkels ME, Hagebeuk EO, et al. Remarkable phenytoin sensitivity in 4 children with SCN8A-related epilepsy: a molecular neuropharmacological approach. Neurotherapeutics. 2016;13:192–7.

    CAS  Article  PubMed  Google Scholar 

  51. Mikati MA, Jiang YH, Carboni M, Shashi V, Petrovski S, Spillmann R, et al. Quinidine in the treatment of KCNT1-positive epilepsies. Ann Neurol. 2015;78:995–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  52. Bearden D, Strong A, Ehnot J, DiGiovine M, Dlugos D, Goldberg EM. Targeted treatment of migrating partial seizures of infancy with quinidine. Ann Neurol. 2014;76:457–61.

    CAS  Article  PubMed  Google Scholar 

  53. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134:2802–18.

    Article  PubMed  Google Scholar 

  54. Strzelczyk A, Kortland LM, Knake S, Rosenow F. Stiripentol for the treatment of super-refractory status epilepticus. Acta Neurol Scand. 2015;132:435–9.

    CAS  Article  PubMed  Google Scholar 

  55. Uchida Y, Kato D, Toyoda T, Oomura M, Ueki Y, Ohkita K, et al. Combination of ketogenic diet and stiripentol for super-refractory status epilepticus: a case report. J Neurol Sci. 2017;373:35–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Divisions of Child and Adolescent Neurology and Epilepsy, Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA

    Katherine C Nickels & Elaine C Wirrell

Authors
  1. Katherine C Nickels
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elaine C Wirrell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elaine C Wirrell.

Ethics declarations

Funding

No funding.

Conflicts of interest

Dr. Nickels and Dr. Wirrell have no conflicts of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nickels, K.C., Wirrell, E.C. Stiripentol in the Management of Epilepsy. CNS Drugs 31, 405–416 (2017). https://doi.org/10.1007/s40263-017-0432-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-017-0432-1

Keywords

  • Carbamazepine
  • Valproic Acid
  • Status Epilepticus
  • GABAA Receptor
  • Levetiracetam